rHIgM12B7 (Mayo Clinic/NCI)

N/A

Report date: 2022/12/31 17:21:47

Base Information

Drug NamerHIgM12B7 (Mayo Clinic/NCI)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSkin MelanomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo ClinicNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteMayo Clinic
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsSkin Melanoma

Other Information

ATC CodeN/A
Related LinksN/A